New study tracks Real-World impact of hemophilia drug on joint bleeds
NCT ID NCT06940830
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study follows 250 people with hemophilia A who are taking efanesoctocog alfa to prevent bleeding. The goal is to see how well the drug protects joints from bleeds over the long term in everyday life. Participants will have their joint bleed rates tracked for several years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sobi Investigational Site
RECRUITINGZagreb, Croatia
-
Sobi Investigational Site
RECRUITINGBrno, Czechia
-
Sobi Investigational Site
RECRUITINGOstrava, Czechia
-
Sobi Investigational Site
RECRUITINGPrague, Czechia
-
Sobi Investigational Site
RECRUITINGBordeaux, France
-
Sobi Investigational Site
RECRUITINGMarseille, France
-
Sobi Investigational Site
RECRUITINGMontpellier, France
-
Sobi Investigational Site
RECRUITINGNantes, France
-
Sobi Investigational Site
RECRUITINGParis, France
-
Sobi Investigational Site
RECRUITINGRennes, France
-
Sobi Investigational Site
RECRUITINGRouen, France
-
Sobi Investigational Site
RECRUITINGBerlin, Germany
-
Sobi Investigational Site
RECRUITINGBonn, Germany
-
Sobi Investigational Site
RECRUITINGFrankfurt am Main, Germany
-
Sobi Investigational Site
RECRUITINGHamburg, Germany
-
Sobi Investigational Site
RECRUITINGMunich, Germany
-
Sobi Investigational Site
RECRUITINGDublin, Ireland
-
Sobi Investigational Site
RECRUITINGTurin, Italy
-
Sobi Investigational Site
RECRUITINGA Coruña, Spain
-
Sobi Investigational Site
RECRUITINGBarcelona, Spain
-
Sobi Investigational Site
RECRUITINGMálaga, Spain
-
Sobi Investigational Site
RECRUITINGPalma de Mallorca, Spain
-
Sobi Investigational Site
RECRUITINGZaragoza, Spain
-
Sobi Investigational Site
RECRUITINGBirmingham, United Kingdom
-
Sobi Investigational Site
RECRUITINGCardiff, United Kingdom
-
Sobi Investigational Site
RECRUITINGLondon, United Kingdom
-
Sobi Investigational Site
RECRUITINGManchester, United Kingdom
Conditions
Explore the condition pages connected to this study.